Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients
Journal
Journal of acquired immune deficiency syndromes (1999)
Journal Volume
86
Journal Issue
4
Pages
473-481
Date Issued
2021
Author(s)
Cheng C.-Y.
Liou B.-H.
Lu P.-L.
Cheng S.-H.
Lee Y.-T.
Liu C.-E.
Yang C.-J.
Tang H.-J.
Lin S.-P.
Ho M.-W.
Huang S.-H.
Tsai H.-C.
Lee C.-H.
Taiwan HIV Study Group
Abstract
BACKGROUND: The efficacy and safety of switching from tenofovir disoproxil fumarate-based antiretroviral therapy to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has not been widely investigated in HIV/hepatit
SDGs
Publisher
NLM (Medline)
Type
journal article